Global Postmenopausal Osteoporosis Market – Industry Trends and Forecast to 2029

Postmenopausal Osteoporosis Market Analysis and Size

As per a latest study, about 75 Million people suffer from osteoporosis disease in Japan, the USA, and Europe. Around 3 million fractures are recorded by Europe annually. Osteoporosis being a silent disease, symptoms will not be visible until a fracture happens in the body. The effect of the disease can be seen in western countries as well now in Latin America and Asia-Pacific. The occurrence is expected to increase further because of sedentary lifestyles and unhealthy eating & drinking habits.

Data Bridge Market Research analyses a growth rate in the global postmenopausal osteoporosis market in the forecast period 2022-2029. The expected CAGR of global postmenopausal osteoporosis market is tend to be around 4% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Postmenopausal Osteoporosis Market Scope and Segmentation

Market Definition

Osteoporosis is a systematic skeletal disorder largely affecting postmenopausal women having the tendency to deteriorate with the age. As a result, the bone loses density and the stability of the inner spongy structure declines until the bone can no longer withstand external stresses and strains the bone then brakes. Osteoporosis has become a global health issue because of its high association with morbidity, mortality, as well as costs. People with low calcium in bone are more prone to this disease ranging to approximately 20% of the patients. Combined hip, forearm, and spine fracture cases are estimated between 40% and 50% worldwide.

Global Postmenopausal Osteoporosis Market Dynamics

Drivers

• Rising Prevalence of Osteoporosis

Increasing osteoporosis prevalence is boosting the market's growth, as more patients would increase demand for the drugs. Furthermore, demand for osteoporosis drugs is increasing constantly. For instance, as per the records of International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures every year, resulting in an osteoporotic fracture every 3 seconds and also it is projected to affect 200 million women worldwide.

• Increasing Incidence in Elderly Population

Osteoporosis cases are mostly witnessed in the age group ≤ 40 years, 41−60 years, and > 60 years. The >60 years group saw the highest number of patients, mostly around 10,275 in 2021 in the U.S. In 2021, treatment eligible population of osteoporosis accounted for 9,511 cases in the U.S. Thus, this elderly population has higher chances of getting this disease boosts the market growth.

Opportunities

• Rising R&D and New Drug Approvals

The unmet needs of patients suffering from postmenopausal osteoporosis are encouraging manufacturers to innovate new solutions. The rising investments in the research and development activities to develop a precise treatment for myelofibrosis is anticipated to boost the growth of the industry in the forecast period. The speedy technological advancements and ongoing clinical trials contribute to industry growth. Other factors such as improved healthcare sector, reimbursement policies, favourable government initiatives, busy lifestyle and changing dietary patterns are also resulting in the industry growth.   

• Increasing Collaborations and Market Expansion

An increase in the commencing of joint ventures between major market players with numerous other factors such as the family history of members diagnosed with osteoporosis disease, long term usage of medicines that affects bone density in the body played an important role in the growth of the market. Thus, these factors are growing the market.

 Restraints/Challenges

• Lack of Awareness

The lack of awareness about the diseased condition and the unavailability of several awareness programs restrict the market growth. The available drugs have not shown disease-modifying activity and are still mostly inadequate for managing major unmet needs.

• High Cost

Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. The loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to nearly 35% - 40% in the first year. This low cost of generics results in higher consumption, although generic drugs cannot achieve or exceed the overall sales of the branded formulation.

This global postmenopausal osteoporosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global postmenopausal osteoporosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Postmenopausal Osteoporosis Market

The outbreak of Covid-19 has majorly impacted the healthcare industry. The National Osteoporosis Foundation has conducted several survey and International Osteoporosis Foundation concluded that the main impact includes delays in scanning for diagnosis, interruptions in the supply of drugs and raw material, an increase in telemedicine consultations, and a decrease in parenteral medicine delivery. COVID-19 is projected to have a major impact on the postmenopausal osteoporosis market, although, with the reducing COVID-19 cases and large-scale vaccination programs, the market is estimated to regain its full potential over the forecast period.

Recent Developments

• In July 2022, Chugai Pharma China Co., Ltd launched Edirol (eldecalcitol) in China after the China National Medical Products Administration (NMPA) approval for treating postmenopausal osteoporosis patients. Edirol is an active vitamin D3 derivative created by Chugai.
• In January 2021, the Asia-Pacific Consortium on Osteoporosis (APCO) launched pan-Asia Pacific clinical practice standards to screen, diagnose, and manage osteoporosis that will significantly target a huge range of high-risk groups. This initiative is anticipated to increase further awareness in the region, which is projected to boost the market in Asia-Pacific.

Global Postmenopausal Osteoporosis Market Scope

The global postmenopausal osteoporosis market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Vitamin D
• Bisphosphonates
• Calcitonin
• Hormone Replacement Therapy
• Estrogen Antagonist,
• Parathyroid Hormone
• Combination Therapy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

 Postmenopausal Osteoporosis Market Regional Analysis/Insights

The global postmenopausal osteoporosis market is analyzed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global postmenopausal osteoporosis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for postmenopausal osteoporosis market throughout the forecasted period due to the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities.

North America dominates the market due to the global leaders in research and development activities, high adoption of treatment procedures and increase in cases of postmenopausal osteoporosis.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Postmenopausal Osteoporosis Market Share Analysis

The global postmenopausal osteoporosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global postmenopausal osteoporosis market.

Key players operating in the global postmenopausal osteoporosis market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (Japan)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.)
• GSK Plc. (U.K.)
• Sun Pharmaceutical Industries Ltd (India)
• Clonz Biotech Pvt. Ltd (India)
• Ligand Pharmaceuticals Incorporated (U.S.)
• Outlook Therapeutics, Inc. (U.S.)
• Paras Biopharmaceuticals Finland Oy (Finland)

SKU-54636